Despite all the hype and the prospect of billions of dollars in federal spending, many biotech companies--and stock analysts--are warily eyeing the market for new avian flu drugs. The Los Angeles Times brings up the case of Vical, which was developing a vaccine for a SARS epidemic that never happened. But despite the extremely difficult process of developing a vaccine for a virus that currently doesn't exist and may never appear, a lineup of biotech companies are plunging ahead. That lineup also includes Vical.
- read this report from the Los Angeles Times for more